ENNOGEN PHARMA LTD

07751819
Active Dartford
0 employees website.com
Life sciences and medical technology
E

ENNOGEN PHARMA LTD

07751819
Founded 24 Aug 2011 Active Dartford, United Kingdom 0 employees website.com
Life sciences and medical technology
Accounts Submitted 24 Oct 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 9 Sept 2025 Next due 7 Sept 2026 2 months remaining
Net assets £2M £64K 2024 year on year
Total assets £2M £335K 2024 year on year
Total Liabilities £106K £399K 2024 year on year
Charges 3
1 outstanding 2 satisfied

Contact & Details

Contact

Registered Address

Unit G4 Riverside Industrial Estate Riverside Way Dartford Kent DA1 5BS

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for ENNOGEN PHARMA LTD (07751819), an active life sciences and medical technology company based in Dartford, United Kingdom. Incorporated 24 Aug 2011. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type total-exemption-full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2013–2024)

Cash in Bank

£55.58k

Increased by £8.12k (+17%)

Net Assets

£1.71M

Increased by £63.79k (+4%)

Total Liabilities

£105.79k

Decreased by £399.19k (-79%)

Turnover

N/A

Employees

N/A

Debt Ratio

6%

Decreased by 18 (-75%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active
Status
Ruprai, Gurdev SinghDirectorBritishUnited Arab Emirates6524 Aug 2011Active

Shareholders

Shareholders (1)

Gurdev Singh Ruprai
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased
Active
Notified 1 Jan 2022
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Gurdev Singh Ruprai

Ceased 1 Jan 2022

Ceased

Group Structure

Group Structure

ENNOGEN PHARMA LTD Current Company

Charges

Charges

1 outstanding 2 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
10 Apr 2026OfficersChange to director Mr Gurdev Singh Ruprai on 1 Apr 2026
24 Oct 2025AccountsAnnual accounts made up to 31 Dec 2024
15 Oct 2025OtherAudit exemption statement of guarantee by parent company for period ending 31/12/24
15 Oct 2025OtherNotice of agreement to exemption from audit of accounts for period ending 31/12/24
1 Oct 2025AccountsAnnual accounts filed
10 Apr 2026 Officers

Change to director Mr Gurdev Singh Ruprai on 1 Apr 2026

24 Oct 2025 Accounts

Annual accounts made up to 31 Dec 2024

15 Oct 2025 Other

Audit exemption statement of guarantee by parent company for period ending 31/12/24

15 Oct 2025 Other

Notice of agreement to exemption from audit of accounts for period ending 31/12/24

1 Oct 2025 Accounts

Annual accounts filed

Recent Activity

Latest Activity

Change to director Mr Gurdev Singh Ruprai on 1 Apr 2026

2 months ago on 10 Apr 2026

Annual accounts made up to 31 Dec 2024

8 months ago on 24 Oct 2025

Audit exemption statement of guarantee by parent company for period ending 31/12/24

8 months ago on 15 Oct 2025

Notice of agreement to exemption from audit of accounts for period ending 31/12/24

8 months ago on 15 Oct 2025

Annual accounts filed

8 months ago on 1 Oct 2025